Free Trial
→ Trump To Relaunch USD? (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.78
-2.6%		$0.99
$0.55
▼
$2.00
$74.27M1.81.03 million shs480,278 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$1.05
-3.2%		$1.13
$0.76
▼
$2.03
$20.13M1.48816,076 shs40,312 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$1.42
-4.8%		$2.03
$1.12
▼
$3.96
$73.79M0.35139,290 shs42,936 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$1.57
+5.7%		$1.56
$0.62
▼
$8.01
$74.17M-2.311.93 million shs242,519 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-6.44%-14.71%-18.43%-15.53%-55.46%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+1.89%-2.70%-12.90%+12.50%+1.89%
Rafael Holdings, Inc. stock logo
RFL
Rafael
-2.63%-0.74%-35.84%-36.66%+10.62%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-12.43%+33.33%-4.52%+97.65%-48.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.78
-2.6%		$0.99
$0.55
▼
$2.00
$74.27M1.81.03 million shs480,278 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$1.05
-3.2%		$1.13
$0.76
▼
$2.03
$20.13M1.48816,076 shs40,312 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$1.42
-4.8%		$2.03
$1.12
▼
$3.96
$73.79M0.35139,290 shs42,936 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$1.57
+5.7%		$1.56
$0.62
▼
$8.01
$74.17M-2.311.93 million shs242,519 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-6.44%-14.71%-18.43%-15.53%-55.46%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+1.89%-2.70%-12.90%+12.50%+1.89%
Rafael Holdings, Inc. stock logo
RFL
Rafael
-2.63%-0.74%-35.84%-36.66%+10.62%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-12.43%+33.33%-4.52%+97.65%-48.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2.50
Moderate Buy$3.33326.80% Upside
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
2.00
HoldN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest COCP, CGTX, ZYBT, and RFL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/21/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/25/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/21/2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
7/20/2026
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D-) ➝ Sell (D)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.39 per shareN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$0.46 per shareN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
$920K80.20N/AN/A$1.91 per share0.74
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$16.64M4.46N/AN/A$0.93 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$23.49M-$0.17N/AN/AN/AN/A-50.17%-40.22%11/5/2026 (Estimated)
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$8.83M-$0.76N/AN/AN/AN/A-207.47%-123.33%11/13/2026 (Estimated)
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$30.52M-$0.68N/AN/AN/A-3,321.74%-41.27%-35.32%10/28/2026 (Estimated)
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-$9.98MN/AN/AN/AN/AN/AN/AN/AN/A

Latest COCP, CGTX, ZYBT, and RFL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.07N/AN/AN/A$5.30 millionN/A
8/13/2026Q2 2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.17-$0.23-$0.06-$0.23$0.11 million$0.11 million
8/6/2026Q2 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.0633-$0.04+$0.0233-$0.04$5.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
7.03
7.03
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
1.24
1.24
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
3.16
3.14
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
6.72%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A

Insider Ownership

CompanyInsider Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
11.11%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
39.40%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
1495.09 million84.53 millionNot Optionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
1019.26 million11.67 millionNot Optionable
Rafael Holdings, Inc. stock logo
RFL
Rafael
2352.00 million34.89 millionOptionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
26947.39 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology (NASDAQ:ZYBT) Shares Up 4.5% - Here's Why
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098017
Zhengye Biotechnology Holding Ltd (ZYBT)
August 28, 2026  |  ru.investing.comhttps://ru.investing.com/equities/zhengye-biotechnology-holding-financial-summary
Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zhengye-biotechnology-regains-nasdaq-minimum-bid-price-compliance?utm_source=marketbeat.com&utm_medium=referral
Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today
August 5, 2026  |  quiverquant.comQ
Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga
July 23, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ZYBT/short-interest
Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity
July 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zhengye-biotechnology-addresses-unusual-nasdaq-trading-activity?utm_source=marketbeat.com&utm_medium=referral
Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)
July 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/zhengye-biotechnology-says-no-material-events-behind-unusual-trading-activity-nasdaqzybt/ar-AA28nX2M
Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity
July 21, 2026  |  quiverquant.comQ
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330458/0/en/zhengye-biotechnology-holding-limited-comments-on-unusual-trading-activity.html
Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today
July 20, 2026  |  quiverquant.comQ
Zhengye Biotechnology Holding Ltd. Class A
July 13, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/ZYBT
Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zhengye-biotechnology-faces-nasdaq-minimum-bid-price-deficiency-after-may-29-notice?utm_source=marketbeat.com&utm_medium=referral
Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307082/0/en/zhengye-biotechnology-holding-limited-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency.html
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/zhengye-biotechnology-holding-limited-announces-fiscal-year-2025-financial-results-302756248.html
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026
April 6, 2026  |  quiverquant.comQ
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
April 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/06/3268492/0/en/zhengye-biotechnology-holding-limited-announces-implementation-of-dual-class-share-structure.html
Zhengye Biotechnology Holding Ltd ZYBT
March 28, 2026  |  morningstar.comM
Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM
March 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zhengye-biotechnology-shareholders-approve-governance-and-share-structure-changes-at-march-24-agm?utm_source=marketbeat.com&utm_medium=referral
Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM
February 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zhengye-biotechnology-director-resigns-nasdaq-independence-deficiency-to-be-addressed-at-march-agm?utm_source=marketbeat.com&utm_medium=referral
Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders
February 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zhengye-biotechnology-holding-limited-issues-2026-chairman-s-letter-to-shareholders-1035807693

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$0.78 -0.02 (-2.58%)
Closing price 03:59 PM Eastern
Extended Trading
$0.77 -0.01 (-1.02%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$1.04 -0.04 (-3.70%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Rafael stock logo

Rafael NYSE:RFL

$1.41 -0.08 (-5.44%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$1.56 +0.09 (+5.74%)
Closing price 03:59 PM Eastern
Extended Trading
$1.56 -0.01 (-0.64%)
As of 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas